Glenmark receives ANDA approvals for generic Lamictal (market size US$62mn)
Glenmark pharma is among more than fifteen other generic players to have USFDA approvals for Lamotrigine (generic version of GSK's Lamictal) to sell, the product in US market.
Lamictal generates annual revenue of US$62mn. Lamictal is an anti-epileptic drugs indicated for Epilepsy and Bipolar disorder. Owing to high competition, we do not expect substantial market share for Glenmark in this market. With this approval, Glenmark is now authorised to sell 80 generic products in US while 38 ANDA remains pending approvals.
....more info
Glenmark pharma is among more than fifteen other generic players to have USFDA approvals for Lamotrigine (generic version of GSK's Lamictal) to sell, the product in US market.
Lamictal generates annual revenue of US$62mn. Lamictal is an anti-epileptic drugs indicated for Epilepsy and Bipolar disorder. Owing to high competition, we do not expect substantial market share for Glenmark in this market. With this approval, Glenmark is now authorised to sell 80 generic products in US while 38 ANDA remains pending approvals.
....more info